---
document_datetime: 2024-09-17 15:18:56
document_pages: 34
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/inflectra-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: inflectra-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 18.0330933
conversion_datetime: 2025-12-29 19:31:28.901533
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Inflectra

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0118              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 10/09/2024                          | n/a                                         |                                  |           |
| IB/0117/G            | This was an application for a group of variations.                                                                                            | 31/07/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | the manufacturing process of the AS - Other variation B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                               |            |     |             | B.I.a.2.z - Changes in   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|--------------------------|
| IB/0116   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by                                                                                                                                                                                          | 17/04/2024 |     | SmPC and PL | the MAH                  |
| IB/0115/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits | 27/11/2023 | n/a |             |                          |
| IA/0114   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the                                                                                                                                                                                                                                                                                                                                           | 29/09/2023 | n/a |             |                          |

<div style=\"page-break-after: always\"></div>

|                     | finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |     |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IA/0113/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites B.I.c.2.b - Change in the specification parameters and/or limits of the immediate packaging of the AS - Addition of a new specification parameter to the specification with its corresponding test method | 29/09/2023 | n/a |                                   |
| IB/0112             | B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)                                                                                                                                                                                                                                                                                                                                       | 14/09/2023 | n/a |                                   |
| IB/0111             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                     | 16/05/2023 | n/a |                                   |
| PSUSA/10759 /202208 | Periodic Safety Update EU Single assessment - infliximab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 14/04/2023 | n/a | PRAC Recommendation - maintenance |
| IB/0110             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 22/12/2022 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |             |                                                                                                                                                                                                                     |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0108/G | This was an application for a group of variations. B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch | 24/11/2022 | n/a        |             |                                                                                                                                                                                                                     |
| IB/0107/G | This was an application for a group of variations. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                       | 29/04/2022 | 21/10/2022 | SmPC and PL | Sections 4.4, 4.5 and 4.6 of the SmPC, Section 2 of the PL and the Patient Reminder Card were updated with information regarding administration of live vaccines to infants exposed to infliximab during pregnancy. |

<div style=\"page-break-after: always\"></div>

| IB/0106   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other                                                                                                                                                                                                                                                                                                                                                                                                        | 22/03/2022   | n/a        |                                  | variation   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------|
| II/0105   | Submission of the final report from study CT-P13 4.2; An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of Inflectra in Patients with Rheumatoid Arthritis (study report excluding the joint analysis of patients in the PERSIST study). The submission of the study report addresses MEA 007.6. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                           | 10/03/2022   | n/a        |                                  |             |
| IB/0103   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                     | 09/12/2021   | n/a        |                                  |             |
| IB/0104/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO | 18/11/2021   | 21/10/2022 | SmPC, Annex II, Labelling and PL |             |

<div style=\"page-break-after: always\"></div>

|           | new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0100/G | This was an application for a group of variations. Submission of the final CSRs for CT-P13 registry studies in Inflammatory Bowel Disease (IBD), Ankylosing Spondylitis (AS) and Rheumatoid Arthritis (RA) initiated with the objective of assessing long- term safety in these indications: • Final report for CT-P13 4.3 (EU and Korean IBD Registry; one study for Remsima® and one study for Inflectra®) • Final report for CT-P13 4.4 (EU and Korean AS Registry; one study for Remsima® and one study for Inflectra®) • Final report for BSRBR-RA Registry (one study equally applicable to Remsima® and Inflectra®) • Final report for RABBIT Registry (one study equally applicable to Remsima® and Inflectra®) C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered | 30/09/2021 | n/a | The current variation concerns the final study reports of post-authorization safety studies and registries listed as category 3 in Risk Management Plan (RMP), to investigate the long-term safety of infliximab in Rheumatoid Arthritis (BSRBR-RA, RABBIT), Inflammatory Bowel Disease (CT-P13 4.3), and Ankylosing Spondylitis (CT-P13 4.4). Observational data derived from these four non- interventional studies did not reveal any new or unexpected safety findings. |

<div style=\"page-break-after: always\"></div>

|         | of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                               |            |            |    |                   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-------------------|
| N/0101  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                | 21/09/2021 | 22/10/2021 | PL |                   |
| IA/0102 | B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall                                                                                                                                                                                                                                | 31/08/2021 | n/a        |    | quality of the AS |
|         | This was an application for a group of variations. B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits | 24/06/2021 | n/a        |    | IA/0099/G         |
| IB/0098 | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                   | 09/06/2021 | n/a        |    |                   |

<div style=\"page-break-after: always\"></div>

| IB/0097   | B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 19/05/2021   | n/a        |                        |           |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-----------|
| IB/0096   | B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 05/03/2021   | 22/10/2021 | SmPC, Labelling and PL |           |
| II/0094/G | This was an application for a group of variations. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.3.c - Change in batch size (including batch size ranges) of AS or intermediate - The change requires assessment of the comparability of a biological/immunological AS B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation | 25/02/2021   | n/a        |                        | B.I.a.2.c |

<div style=\"page-break-after: always\"></div>

|           | the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation   |            |            |             |           |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------|
| IB/0095   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                    | 28/01/2021 | n/a        |             |           |
|           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                | 23/10/2020 | 22/10/2021 | SmPC and PL | IAIN/0093 |
| N/0090    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                              | 09/09/2020 | 22/10/2021 | PL          |           |
| IB/0091   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                          | 08/09/2020 | n/a        |             |           |
| IB/0092   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                 | 07/09/2020 | n/a        |             |           |
| IA/0089/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                               | 03/08/2020 | n/a        |             |           |

<div style=\"page-break-after: always\"></div>

|                     | B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.c.2.a - Change in the specification parameters and/or limits of the immediate packaging of the AS - Tightening of specification limits                                                                                                                                                                                                                          |            |     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0088/G           | This was an application for a group of variations. B.I.a.4.d - Change to in-process tests or limits applied during the manufacture of the AS - Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the AS B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                     | 02/07/2020 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| PSUSA/10759 /201908 | Periodic Safety Update EU Single assessment - infliximab                                                                                                                                                                                                                                                                                                                                                                                                                                        | 17/04/2020 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0080             | Submission of the final clinical study report for C1231001 (CONNECT-IBD) study; a non- interventional study designated as a Post Authorisation Safety Study conducted voluntarily to capture data from real-world clinical practice to characterise the population and document drug utilisation patterns. In addition, available safety data and data on the effectiveness of CT-P13 in the context of standard of care utilisation of Remicade (reference medicinal product) was collected in | 17/04/2020 | n/a | This study had been used as a data source to investigate the long-term safety and effectiveness in inflammatory bowel disease (Crohn's disease or ulcerative colitis) with emphasis on TB and other serious infection. While the inherent limitations exist in relation to group size, selection bias within each treatment group (CT-P13 vs Remicade) and sub-group size (UC vs CD) for any comparisons, the study confirmed that the safety profiles for each treatment group were consistent with the expected safety profile of |

<div style=\"page-break-after: always\"></div>

|           | patients with Crohn's disease or ulcerative colitis. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                      |            |     | infliximab and did not identify any new safety risk.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0079   | Submission of the final clinical study report for C1231002 (PERSIST) study, an observational cohort study designed to evaluate real life drug persistence in biologic naive rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients receiving CT-P13 or those switched to CT-P13 from stable treatment with Remicade (reference medicinal product). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 17/04/2020 | n/a | No new safety information was identified from the submitted data. This study was listed as EU RMP in order to further characterise the safety profile of CT-P13 including long-term safety and Important identified risks: serious infections including sepsis (initially including tuberculosis), demyelinating disorders and malignancy but there was a small sample size resulting from early study termination. The most frequent treatment related adverse drug reactions of serious infections and infusion reactions are already adequately addressed in the Product Information. No meaningful information on demyelinating disorders and malignancy were identified. The CHMP stressed that the submitted results were limited, however, cconsidering the totality of the safety data available for CT-P13 and the infliximab originator, it is anticipated that additional data that could have been gathered if this study would have been conducted for the full time period planned, would likely have been limited. |
| IA/0087   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                        | 13/03/2020 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0081/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 06/02/2020 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.b.1.e - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a specification parameter which may have a significant effect on the overall quality of the AS and/or the FP B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.II.b.5.e - Change to in-process tests or limits applied during the manufacture of the finished product - Widening of the approved IPC limits, which may have a significant effect on overall quality of the finished product B.II.f.1.e - Stability of FP - Change to an approved   |            |            |             |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| IB/0086 | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 19/12/2019 | n/a        |             |
| IB/0084 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 09/12/2019 | 10/08/2020 | SmPC, Annex |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | of the same change for the reference - Implementation of change(s) for which NO additional data is required to be submitted by MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     | II and PL   | assessment product new the   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|------------------------------|
| IA/0083/G | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.II.b.3.a - Change in the manufacturing process of intermediate product - Minor change | 30/10/2019 | n/a |             | the finished or              |

<div style=\"page-break-after: always\"></div>

| IB/0082/G   | This was an application for a group of variations. B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line) B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits   | 25/10/2019   | n/a        |                        |                |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|----------------|
| IB/0078/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing                        | 28/08/2019   | 10/08/2020 | Annex II and Labelling | authorisation, |
| IB/0077     | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                                         | 19/06/2019   | n/a        |                        |                |
| IB/0075/G   | This was an application for a group of variations. A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                                                                                                      | 07/06/2019   | 16/09/2019 | SmPC, Annex II and PL  |                |

<div style=\"page-break-after: always\"></div>

|         | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)                               |            |            |             | manufacturing sites      |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------|
| N/0076  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                 | 09/04/2019 | 16/09/2019 | PL          |                          |
| IB/0074 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                   | 03/04/2019 | 16/09/2019 | SmPC and PL |                          |
| II/0072 | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                    | 14/03/2019 | n/a        |             |                          |
|         | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing including the RMP - Implementation of | 18/02/2019 | 16/09/2019 | SmPC and PL | IB/0073/G authorisation, |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | wording agreed by the competent authority C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |                                                      |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------|
| II/0070/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial replacement of a | 31/01/2019 | n/a | change to or biological/immunological/immunochemical |

<div style=\"page-break-after: always\"></div>

|           | method or a method using a biological reagent for a biological AS B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.d.1.a.1 - Stability of AS - Change in the re-test period/storage period - Reduction B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a   |            |            |    |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|
| IB/0068/G | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 07/11/2018 | n/a        |    |
| N/0071    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 24/10/2018 | 16/09/2019 | PL |

<div style=\"page-break-after: always\"></div>

| IB/0069             | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                         | 18/10/2018   | 16/09/2019   | SmPC and PL            |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------------------------------|
| IB/0067             | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                           | 18/10/2018   | n/a          |                        |                                   |
| IB/0065/G           | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 24/09/2018   | 16/09/2019   | SmPC, Labelling and PL |                                   |
| PSUSA/10106 /201801 | Periodic Safety Update EU Single assessment - infliximab (biosimilars)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 06/09/2018   | n/a          |                        | PRAC Recommendation - maintenance |
| IA/0066/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 31/08/2018   | n/a          |                        |                                   |

<div style=\"page-break-after: always\"></div>

|           | manufacturing sites B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished   |            |            |                     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------|
| IB/0063/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 30/08/2018 | n/a        |                     |
| T/0064    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 17/07/2018 | 30/07/2018 | SmPC, Labelling and |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0061 | To submit the final report from study CT-P13 3.4, listed as a category 3 study in the RMP. A randomized, double-blind, parallel-group, Phase 3 study to demonstrate noninferiority in efficacy and to assess safety of CT-P13 compared to Remicade in patients with active Crohn's disease. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 19/07/2018 | n/a        |                        | The non-inferiority of efficacy was demonstrated in the primary endpoint and the comparability of the secondary efficacy endpoints supported the biosimilarity with Remicade. Mean serum concentrations were comparable and the results of biomarkers were generally similar between the treatment groups. The overall safety profile in this study was consistent with the known safety profile of Remicade; there were no new or unexpected safety findings observed in this study and no update to the product information was considered necessary. |
| II/0060 | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                            | 12/07/2018 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| R/0056  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                   | 26/04/2018 | 21/06/2018 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Inflectra in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                                                                                                                                 |
| IB/0059 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                              | 27/02/2018 | 08/05/2018 | SmPC and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| II/0057             | B.II.b.3.c - Change in the manufacturing process of the finished or intermediate product - The product is a biological/immunological medicinal product and the change requires an assessment of comparability                                                                                       | 15/02/2018   | n/a        |                 |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------------------------------|
| II/0054             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                       | 08/02/2018   | n/a        |                 |                                   |
| IA/0058             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                       | 11/12/2017   | n/a        |                 |                                   |
| N/0055              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                    | 10/11/2017   | 08/05/2018 | PL              |                                   |
| PSUSA/10106 /201701 | Periodic Safety Update EU Single assessment - infliximab (biosimilars)                                                                                                                                                                                                                              | 01/09/2017   | n/a        |                 | PRAC Recommendation - maintenance |
| IAIN/0053           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                              | 20/07/2017   | 08/05/2018 | Annex II and PL |                                   |
| II/0050/G           | This was an application for a group of variations. B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products B.II.b.3.a - Change in the manufacturing process of | 29/06/2017   | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

|         | the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                          |            |            |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0052 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                              | 24/05/2017 | 08/05/2018 | Annex II         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| N/0049  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                          | 16/02/2017 | 08/05/2018 | Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0048 | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                              | 21/12/2016 | n/a        |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0047 | Update of the RMP (v 7.0) to merge the RMPs for Remsima and Inflectra. The variation leads to amendments to the Risk Management Plan (RMP). C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 15/12/2016 | n/a        |                  | Inflectra and Remsima are two biosimilar infliximab products. The MAHs for these two products will share the safety database and from 2016 will submit a single PSUR covering both products. Accordingly the MAHs have integrated the RMPs into a single RMP covering both products. The proposed post-authorisation pharmacovigilance development plan is sufficient to identify and characterise the risks of the product. There are no changes to the routine and additional risk minimisation measures as a consequence of the integration of the separate RMPs to form the Remsima/Inflectra RMP version 7.0. |
| IB/0046 | C.I.2.a - Change in the SPC, Labelling or PL of a                                                                                                                                                                                                                                         | 22/09/2016 | 12/12/2016 | SmPC and PL      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                     | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                        |            |            |    |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|-----------------------------------|
| PSUSA/10106 /201601 | Periodic Safety Update EU Single assessment - infliximab (biosimilars)                                                                                                                                                                                                            | 02/09/2016 | n/a        |    | PRAC Recommendation - maintenance |
| N/0045              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                  | 22/08/2016 | 12/12/2016 | PL |                                   |
| IB/0044             | B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation                                                                                                                                                                                                      | 28/07/2016 | n/a        |    |                                   |
| II/0041             | B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                                                                            | 28/07/2016 | n/a        |    |                                   |
| N/0043              | Update of the package leaflet with revised contact details of the local representatives for Belgium, Germany, Spain, Ireland, Luxembourg, the Netherlands, Austria and Portugal. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 17/06/2016 | 12/12/2016 | PL |                                   |
| IG/0693             | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                | 02/06/2016 | n/a        |    |                                   |

<div style=\"page-break-after: always\"></div>

| II/0034             | Submission of a final clinical study report B2P13111 (Extension Study of the Phase I/II Clinical Study of CT P13 in Treatment of Patients with Rheumatoid Arthritis (Japan)) in order to fulfil the post approval measure MEA 006. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   | 25/02/2016   | n/a        |                                  |                                                                                                                                                                                                                                                                                                       |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10106 /201507 | Periodic Safety Update EU Single assessment - infliximab (biosimilars)                                                                                                                                                                                                                                                                                                             | 11/02/2016   | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                     |
| II/0037             | B.II.f.1.c - Stability of FP - Change in storage conditions for biological medicinal products, when the stability studies have not been performed in accordance with an approved stability protocol                                                                                                                                                                                | 28/01/2016   | 12/12/2016 | SmPC, Labelling and PL           | Inflectra may be stored at temperatures up to a maximum of 25°C for a single period of up to 6 months, but not exceeding the original expiry date. The new expiry date must be written on the carton. Upon removal from refrigerated storage, Inflectra must not be returned to refrigerated storage. |
| IG/0645             | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                    | 17/12/2015   | n/a        |                                  |                                                                                                                                                                                                                                                                                                       |
| IB/0038/G           | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by                                                                            | 15/12/2015   | 12/12/2016 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |            |     |             |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| IB/0035/G | application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line) B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation | 27/11/2015 | n/a | This was an |
| IB/0033   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 06/10/2015 | n/a |             |

<div style=\"page-break-after: always\"></div>

| II/0030             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                             | 24/09/2015   | n/a   |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| II/0026/G           | This was an application for a group of variations. B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                        | 24/09/2015   | n/a   |                                   |
| PSUSA/10106 /201501 | Periodic Safety Update EU Single assessment - infliximab (biosimilars)                                                                                                                                                                                                                                                                                                                                                                                                     | 10/09/2015   | n/a   | PRAC Recommendation - maintenance |
| IA/0032/G           | This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process | 24/07/2015   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|           | manufacture of the finished product - Tightening of in-process limits B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method   |            |            |                        | applied during the   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------|
| IB/0029   | B.I.c.1.z - Change in immediate packaging of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 09/07/2015 | n/a        |                        |                      |
| IAIN/0031 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 01/07/2015 | 23/09/2015 | SmPC, Labelling and PL |                      |
| IG/0555   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                                                            | 22/05/2015 | n/a        |                        |                      |
| IB/0025   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                              | 25/03/2015 | n/a        |                        |                      |
| IB/0024   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 09/03/2015 | 23/09/2015 | SmPC                   |                      |

<div style=\"page-break-after: always\"></div>

|                     | (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |          |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------|
| IAIN/0023           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 19/02/2015 | n/a        |          |                                   |
| PSUSA/10106 /201407 | Periodic Safety Update EU Single assessment - infliximab (biosimilars)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 12/02/2015 | n/a        |          | PRAC Recommendation - maintenance |
| II/0015/G           | This was an application for a group of variations. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method B.I.b.1.g - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Widening of the approved specs for starting mat./intermediates, which may have a significant effect on the quality of the AS and/or the FP B.I.a.4.d - Change to in-process tests or limits applied during the manufacture of the AS - Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the | 22/01/2015 | 23/09/2015 | Annex II |                                   |

<div style=\"page-break-after: always\"></div>

|           | - Changes in the manufacturing process of AS - Minor change in the manufacturing process the AS                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |             | B.I.a.2.a the of   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------|
| IB/0020/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.1.z - Replacement or addition of a for the FP - Other variation | 09/01/2015 | n/a        |             | manufacturing site |
| IB/0022   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                         | 06/01/2015 | 23/09/2015 | SmPC and PL |                    |
| II/0017   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                        | 20/11/2014 | n/a        |             |                    |
| IA/0019/G | This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS -                                                                                                                                                                                                                                                                                                                                                       | 30/10/2014 | n/a        |             |                    |

<div style=\"page-break-after: always\"></div>

|           | Tightening of in-process limits B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material                                            |            |            |             |                                   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUV/0012 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 09/10/2014 | n/a        |             | PRAC Recommendation - maintenance |
| IA/0014/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 25/09/2014 | 23/09/2015 | Annex II    |                                   |
| IG/0477   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                  | 03/09/2014 | n/a        |             |                                   |
| IB/0013/G | This was an application for a group of variations. Update of section 4.4 of the SmPC to mention that                                                                                                                                                                                                                                                                                                                                                                                             | 10/07/2014 | 30/09/2014 | SmPC and PL |                                   |

<div style=\"page-break-after: always\"></div>

|           | cases of active tuberculosis have been reported in patients treated with infliximab during and after treatment for latent tuberculosis. Update of section 4.4 and 4.8 of the SmΡC to mention that the vast majority of HSTCL cases have occurred ίπ patients with Crohn's disease or ulcerative colitis. The Package leaflet is updated accordingly. Furthermore the MAH took the opportunity to update the details of the local representative in Austria. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by   |            |     |            |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------|
| II/0009/G | This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 26/06/2014 | n/a | of studies |

<div style=\"page-break-after: always\"></div>

| II/0008/G   | This was an application for a group of variations. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                             | 26/06/2014   | n/a        |      |                    |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|--------------------|
| IB/0011/G   | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved | 17/06/2014   | 30/09/2014 | SmPC | stability protocol |
| II/0003/G   | This was an application for a group of variations. Addition of a manufacturing site for the fill, finish and secondary packaging of the finished product B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any operation(s) take place, except batch | 22/05/2014   | n/a        |      | manufacturing      |

<div style=\"page-break-after: always\"></div>

|           | release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                                                                      |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0007   | Submission of the final study report of Study CT P13 1.2: a randomized, double-blind, parallel-group, Phase 1 study to evaluate the initial pharmacokinetics, efficacy, and safety of CT P13 compared with Remicade when co-administered with methotrexate in patients with active rheumatoid arthritis in order to fulfil the post-authorisation measure MEA 001. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 20/03/2014 | n/a        |      | Results of the final week 102 report of Study CT P13 1.2 showed that Cmax values were comparable in groups after Doses 1, 2 and 3 with a spike in Cmax in both treatment groups at Dose 2 (Week 2). CT-P13 showed a pharmacodynamic profile that is similar to Remicade. The trial is too small to draw any conclusions on the efficacy and safety of CT-P13 relative to the reference product. The results with respect to efficacy and safety variables in this study do not, however, provide grounds to reconsider the conclusions drawn to date on the therapeutic similarity of CT-P13 and the reference product. |
| IB/0010/G | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                              | 17/03/2014 | 30/09/2014 | SmPC |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IAIN/0006 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the                                                                                                                                                                                                                                                                                                                          | 10/01/2014 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|             | PSMF location                                                                                                                                                                                                                                                                                                                                                                  |            |            |                        |               |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------|
| IB/0005     | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                               | 06/01/2014 | n/a        |                        |               |
| IB/0004     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                   | 16/12/2013 | 30/09/2014 | SmPC, Labelling and PL |               |
| IAIN/0002   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                             | 11/10/2013 | n/a        |                        |               |
| IAIN/0001/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - batch control/testing | 11/10/2013 | 30/09/2014 | Annex II and PL        | Not including |